About Melanopsin
Melanopsin (OPN4) is a protein
from Homo sapiens identified by UniProt accession
Q9UHM6, 478 residues long.
MolForge cross-references it against 0 known binders and
135 disease associations.
Target properties
| Protein name | Melanopsin |
|---|
| UniProt accession | Q9UHM6 |
|---|
| Gene | OPN4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 478 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (135)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.25
- ovarian cancer · score 0.24
- breast adenocarcinoma · score 0.24
- thyroid gland adenocarcinoma · score 0.23
- neutrophil count · score 0.19
- breast milk measurement · score 0.12
- glaucoma · score 0.08
- diabetes mellitus · score 0.06
- neoplasm · score 0.05
- heel bone mineral density · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UHM6-F1 | alphafold | PREDICTED | 74.35 | — |
Amino-acid sequence (478 residues)
MNPPSGPRVP PSPTQEPSCM ATPAPPSWWD SSQSSISSLG RLPSISPTAP GTWAAAWVPL PTVDVPDHAH YTLGTVILLV GLTGMLGNLT VIYTFCRSRS LRTPANMFII NLAVSDFLMS FTQAPVFFTS SLYKQWLFGE TGCEFYAFCG ALFGISSMIT LTAIALDRYL VITRPLATFG VASKRRAAFV LLGVWLYALA WSLPPFFGWS AYVPEGLLTS CSWDYMSFTP AVRAYTMLLC CFVFFLPLLI IIYCYIFIFR AIRETGRALQ TFGACKGNGE SLWQRQRLQS ECKMAKIMLL VILLFVLSWA PYSAVALVAF AGYAHVLTPY MSSVPAVIAK ASAIHNPIIY AITHPKYRVA IAQHLPCLGV LLGVSRRHSR PYPSYRSTHR STLTSHTSNL SWISIRRRQE SLGSESEVGW THMEAAAVWG AAQQANGRSL YGQGLEDLEA KAPPRPQGHE AETPGKTKGL IPSQDPRM
Explore Melanopsin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets